Legend Biotech (LEGN) Capital Expenditures (2019 - 2026)

Legend Biotech (LEGN) has reported Capital Expenditures for 8 consecutive years, with $7.5 million the latest figure, recorded in Q1 2026.

• Quarterly Capital Expenditures rose 275.0% year-over-year to $7.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$8.7 million (down 115.21% YoY) and the FY2024 annual result came in at $14.1 million, down 29.77% from the prior year.
• Capital Expenditures climbed to $7.5 million in Q1 2026 per LEGN's latest filing, from -$5.0 million in the prior quarter.
• Over the last five years, Capital Expenditures for LEGN reached as high as $35.8 million in Q4 2023 and fell as low as -$20.9 million in Q4 2022.
• A 5-year average of $579437.5 and a median of $276500.0 in 2022 frame the typical range for Capital Expenditures.
• Annual changes were most pronounced in 2022 — Capital Expenditures soared 2680.0% — and 2025, when it plunged 4583.39%.
• Year by year, Capital Expenditures stood at -$20.9 million in 2022, then surged by 271.18% to $35.8 million in 2023, then dropped by 27.89% to $25.8 million in 2024, then plunged by 119.38% to -$5.0 million in 2025, then soared by 249.85% to $7.5 million in 2026.
• According to Business Quant data, Capital Expenditures over the past three periods registered $7.5 million, -$5.0 million, and -$13.2 million for Q1 2026, Q3 2025, and Q2 2025 respectively.